Ardea, headquartered in San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer, inflammatory diseases and human immunodeficiency virus (HIV). Ardea was formerly known as IntraBiotics Pharmaceuticals, Inc. and was incorporated in the State of Delaware in 1994.

In December 2006, we acquired intellectual property and other assets related to three distinct pharmaceutical research and development programs from Valeant Research & Development, Inc., or Valeant.  Since that time, we have successfully advanced all of these programs and expanded beyond them to establish our current pipeline of product candidates.

Our Business Strategy

We believe that we are well-positioned to create shareholder value given our ability to rapidly and cost-effectively advance our clinical-stage product candidates, either independently or in collaboration with pharmaceutical or other biotechnology companies.

Our most advanced clinical-stage product candidates include RDEA594, a URAT1 transporter inhibitor for the treatment of hyperuricemia and gout; RDEA119, a specific inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer and inflammatory diseases; and RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV.